Tirzepatide vs Semaglutide 2026: Updated Head-to-Head Comparison
Updated 2026 comparison of tirzepatide vs semaglutide for weight loss. Head-to-head clinical trial data, side effect profiles, regulatory status, and which is right for you.
How should I compare tirzepatide and semaglutide treatment through Trimi?
A licensed provider reviews your assessment and decides whether either treatment is appropriate. Compare Trimi's full plan charge, payment commitment and included care separately from that clinical decision. Compounded semaglutide and compounded tirzepatide are prepared per prescription and are not FDA-approved.
What are Trimi's own plan charges?
Compounded semaglutide prescribed through Trimi is $175 billed monthly, $435 billed every 3 months ($145 a month equivalent), $720 upfront for 6 months ($120 a month equivalent), or $1,188 upfront for a 12-month commitment ($99 a month equivalent). A prepaid monthly equivalent is not a monthly charge.
Compounded tirzepatide prescribed through Trimi is $235 billed monthly, $597 billed every 3 months ($199 a month equivalent), $1,050 upfront for 6 months ($175 a month equivalent), or $1,500 upfront for a 12-month commitment ($125 a month equivalent). A prepaid monthly equivalent is not a monthly charge.
| Plan | Compounded semaglutide | Compounded tirzepatide |
|---|---|---|
| Monthly | $175 billed monthly$175 a month | $235 billed monthly$235 a month |
| Quarterly, 3-month commitment | $435 billed every 3 months$145 a month equivalent | $597 billed every 3 months$199 a month equivalent |
| 6-month, 6-month commitment | $720 billed upfront$120 a month equivalent | $1,050 billed upfront$175 a month equivalent |
| Annual, 12-month commitment | $1,188 billed upfront$99 a month equivalent | $1,500 billed upfront$125 a month equivalent |
Each plan includes medication if prescribed, injection supplies, provider access and shipping, with no separate enrollment, consultation, membership or shipping fee. The price is the same at every prescribed dose. A licensed provider decides whether to prescribe. Compounded medications are not FDA-approved.
Plan and refund sources checked October 30, 2026 (UTC). Sources: semaglutide plans, tirzepatide plans and refund policy. FDA compounding guidance distinguishes compounded preparations from FDA-approved drugs; this plan table does not establish clinical equivalence or savings relative to a brand-name prescription.
More on GLP-1 Treatment Comparisons
Written by Trimi Editorial Team
The 2026 Landscape: What's New Since Last Year
SURMOUNT-5 was the first randomized head-to-head trial of tirzepatide and semaglutide in adults with obesity, or overweight with a weight-related condition, without type 2 diabetes. What was previously inferred from separate trials conducted in different populations can now be compared directly in that population.
The access landscape has also shifted. Brand products remain FDA-approved finished drugs supplied by their manufacturers. Compounded semaglutide and compounded tirzepatide are prepared per individual prescription by state-licensed 503A compounding pharmacies when a licensed clinician determines that a compounded preparation is clinically appropriate for that specific patient; compounded preparations are not FDA-approved as drugs. Understanding these dynamics is essential for making the right choice in 2026.
Mechanism of Action: GIP+GLP-1 vs GLP-1 Alone
Understanding why tirzepatide outperforms semaglutide requires understanding the incretin system. Both drugs mimic gut hormones that regulate appetite and blood sugar after eating, but they target different receptors.
Semaglutide (GLP-1 Only)
- Activates GLP-1 receptors in brain, gut, pancreas
- Reduces appetite and food intake
- Slows gastric emptying
- Stimulates insulin, suppresses glucagon
- Mean 14.9% weight reduction at 68 weeks (STEP 1)
Tirzepatide (GIP + GLP-1)
- Activates both GLP-1 and GIP receptors
- GIP enhances fat tissue metabolism directly
- Additive satiety effects via dual pathways
- Greater improvement in insulin sensitivity
- Mean 20.9% weight reduction at 72 weeks (SURMOUNT-1)
The GIP receptor's role in adipose tissue is particularly important. GIP receptors in fat cells regulate lipid uptake and storage, and when co-activated with GLP-1 receptors, appear to produce synergistic effects on fat mobilization and energy expenditure that explain tirzepatide's superior weight loss outcomes.
Head-to-Head Clinical Results: SURMOUNT-5 and Beyond
SURMOUNT-5 (NCT05822830, published in NEJM in 2025) enrolled 751 adults with obesity, or overweight with a weight-related condition, without type 2 diabetes and randomized them to tirzepatide (10 mg or 15 mg) or semaglutide (1.7 mg or 2.4 mg) for 72 weeks; our SURMOUNT-5 explainer walks through the design and results.
SURMOUNT-5 Key Results (72 weeks)
Tirzepatide (pooled 10+15mg)
Mean weight loss: 20.2%
≥25% loss: 31.6% of participants
Semaglutide (1.7 or 2.4 mg)
Mean weight loss: 13.7%
≥25% loss: 16.1% of participants
The relative superiority of tirzepatide was consistent across subgroups including sex, age, baseline BMI, and presence of metabolic comorbidities. Importantly, both drugs demonstrated clinically meaningful weight loss, a patient losing 13.7% of body weight on semaglutide has achieved a significant, health-improving outcome. All of the figures above are trial averages reported in controlled studies, not guaranteed or typical individual outcomes. Individual results vary.
Side Effect Profiles Compared
Both medications share a class effect of gastrointestinal side effects, which are most pronounced during dose escalation.
Neither medication is significantly safer than the other from a gastrointestinal standpoint. Serious adverse events including pancreatitis are rare with both. Both carry warnings for thyroid C-cell tumors based on rodent data (though not established in humans) and are contraindicated with a personal or family history of medullary thyroid carcinoma or MEN2 syndrome.
Regulatory Status: Brand Products vs Compounded Preparations
Before comparing anything else about how you obtain these medications, it is worth being precise about what each product legally is. The two categories are not interchangeable, and they are regulated differently.
Wegovy and Ozempic (semaglutide)
Finished drug products manufactured by Novo Nordisk and reviewed by the FDA for safety, effectiveness, and manufacturing quality. Wegovy carries an obesity indication; Ozempic carries a type 2 diabetes indication. Insurance coverage varies widely by plan.
Zepbound and Mounjaro (tirzepatide)
Finished drug products manufactured by Eli Lilly and reviewed by the FDA for safety, effectiveness, and manufacturing quality. Zepbound carries an obesity indication; Mounjaro carries a type 2 diabetes indication. Insurance coverage varies widely by plan.
Compounded semaglutide and compounded tirzepatide
Prepared per individual prescription by a state-licensed 503A compounding pharmacy when a licensed clinician determines that a compounded preparation is clinically appropriate for that specific patient. Compounded preparations are not reviewed by the FDA for safety, effectiveness, or manufacturing quality. They are not generic versions of, or substitutes for, the brand products.
Whether a compounded preparation is appropriate for you is a clinical judgment made by a licensed prescriber based on your history, and not a decision to make from a comparison table. For a deeper look at how the two categories differ, see compounded semaglutide vs Wegovy.
Who Should Choose Which Medication?
The right choice depends on individual clinical factors, cost, and goals. Here is a practical framework:
Consider Semaglutide When...
- You have already responded well to GLP-1 therapy
- Insurance covers Wegovy or Ozempic
- You have cardiovascular disease (SELECT trial CV benefit data)
- Goal weight loss is 10–15% of body weight
- Prescriber is more familiar with semaglutide
Consider Tirzepatide When...
- Maximum weight loss is the priority
- Plateaued or under-responded to semaglutide
- Type 2 diabetes with need for A1c improvement
- Significant insulin resistance present
- Insurance covers Zepbound or Mounjaro
Decide with a clinician, not a comparison table
Not sure which molecule fits your history? Talk to a provider.
Prior response, comorbidities, and tolerability decide this, and those are questions for a licensed clinician. Trimi plans include ongoing provider messaging and prescribed dose adjustments. Compounded semaglutide prescribed through Trimi is $175 billed monthly, $435 billed every 3 months ($145 a month equivalent), $720 upfront for 6 months ($120 a month equivalent), or $1,188 upfront for a 12-month commitment ($99 a month equivalent). A prepaid monthly equivalent is not a monthly charge. Compounded tirzepatide prescribed through Trimi is $235 billed monthly, $597 billed every 3 months ($199 a month equivalent), $1,050 upfront for 6 months ($175 a month equivalent), or $1,500 upfront for a 12-month commitment ($125 a month equivalent). A prepaid monthly equivalent is not a monthly charge. Compounded preparations are made per individual prescription by a state-licensed 503A pharmacy and are not FDA-approved as drugs. Individual results vary.
Trimi's compounded tirzepatide is $235 billed monthly or $125 a month on the annual plan ($1,500 upfront, 12-month commitment); the full tirzepatide plan table lists every plan, what is included and the renewal terms.
Trimi's compounded semaglutide is $175 billed monthly or $99 a month on the annual plan ($1,188 upfront, 12-month commitment); see the semaglutide plan table for every plan and its renewal terms.
Switching From Semaglutide to Tirzepatide
Switching between these medications is a decision for your prescribing provider. Points to discuss include:
- Starting dose: tirzepatide is started at 2.5 mg
- Side effects: report gastrointestinal effects to your provider during the transition
- Dose increases: at intervals of at least 4 weeks, as your provider directs
For a detailed comparison including older alternatives, see our article on semaglutide vs tirzepatide vs phentermine vs metformin. If your current medication has stopped producing results, we cover the options in what to do when Ozempic stops working.
Trimi vs. TrimRx: Two Different Companies
Trimi Health at trytrimi.com and TrimRx at trimrx.com are separate, unaffiliated companies. Trimi publishes its own plan charges and identifies BelieveRx, a state-licensed 503A compounding pharmacy in Texas, license #35264. Trimi has a commercial relationship with BelieveRx. A licensed provider decides whether to prescribe, and compounded medications are not FDA-approved.
Comparing the two directly? See our head-to-head: TrimRx vs Trimi.
Frequently Asked Questions
What does each Trimi semaglutide or tirzepatide plan cost?
Compounded semaglutide prescribed through Trimi is $175 billed monthly, $435 billed every 3 months ($145 a month equivalent), $720 upfront for 6 months ($120 a month equivalent), or $1,188 upfront for a 12-month commitment ($99 a month equivalent). A prepaid monthly equivalent is not a monthly charge. Compounded tirzepatide prescribed through Trimi is $235 billed monthly, $597 billed every 3 months ($199 a month equivalent), $1,050 upfront for 6 months ($175 a month equivalent), or $1,500 upfront for a 12-month commitment ($125 a month equivalent). A prepaid monthly equivalent is not a monthly charge.
Does a higher prescribed dose change my plan price?
No. Trimi's plan price is the same at every prescribed dose. Whether a dose change is appropriate is a decision for your provider.
Who decides which medication is appropriate?
A licensed provider through Arora Health reviews your assessment and decides whether to prescribe. Choosing a medication or completing an assessment does not mean you are approved. Follow your prescription and pharmacy label.
What does the plan price include?
Each Trimi plan includes medication if prescribed, injection supplies, provider access and shipping, with no separate enrollment, consultation, membership or shipping fee. The price is the same at every prescribed dose. A licensed provider decides whether to prescribe. Compounded medications are not FDA-approved.
Which compounding pharmacy does Trimi identify?
Trimi identifies BelieveRx, a state-licensed 503A compounding pharmacy in Texas, license #35264. Trimi has a commercial relationship with BelieveRx. The dispensing pharmacy is identified on your prescription label. Compounded medications are not FDA-approved.
What continuation and refund terms should I confirm?
Monthly and quarterly plans renew automatically unless renewal is turned off. Ask Support to confirm continuation and future billing for a 6-month or annual plan. Turning off renewal does not refund a term already paid for. Cancellation and early-exit requests follow the refund policy. If a licensed provider determines treatment is not appropriate, the order is refunded in full under that policy.
Is tirzepatide better than semaglutide for weight loss in 2026?
In their pivotal trials, tirzepatide produced a mean weight reduction of approximately 20.9% at 72 weeks (SURMOUNT-1) and semaglutide 2.4mg produced approximately 14.9% at 68 weeks (STEP 1). The SURMOUNT-5 head-to-head trial published in 2025 compared the two directly and reported greater mean weight loss with tirzepatide. These are trial averages, not guaranteed or typical individual outcomes, and individual results vary. Both medications produced clinically meaningful weight loss in their trials.
What is the main mechanism difference between tirzepatide and semaglutide?
Semaglutide activates only GLP-1 receptors, which regulate appetite, gastric emptying, and insulin secretion. Tirzepatide activates both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors simultaneously. The dual mechanism appears to produce additive effects on satiety and fat metabolism, contributing to tirzepatide's superior weight loss outcomes.
What is the difference between brand-name and compounded tirzepatide or semaglutide?
The difference is regulatory, not just commercial. Wegovy and Ozempic (semaglutide) and Zepbound and Mounjaro (tirzepatide) are FDA-approved finished drugs manufactured by their brand manufacturers and dispensed as approved products. Compounded semaglutide and compounded tirzepatide are prepared per individual prescription by a state-licensed 503A compounding pharmacy when a licensed clinician determines that a compounded preparation is clinically appropriate for that specific patient. Compounded preparations are not FDA-approved as drugs and are not evaluated by the FDA for safety, effectiveness, or manufacturing quality. Which pathway is appropriate is a clinical decision made with your prescriber.
What does the SURMOUNT-5 trial tell us about tirzepatide vs semaglutide?
SURMOUNT-5 was the first direct head-to-head randomized controlled trial comparing tirzepatide (10mg/15mg) vs semaglutide (1.7 mg or 2.4 mg) in people with obesity without diabetes. Results published in 2025 showed tirzepatide produced 20.2% mean body weight loss vs 13.7% for semaglutide over 72 weeks. More tirzepatide participants achieved the ≥25% weight loss threshold (31.6% vs 16.1%). These are trial averages; individual results vary.
Which has worse side effects: tirzepatide or semaglutide?
Both medications share a similar gastrointestinal side effect profile: nausea, vomiting, diarrhea, and constipation are most common, especially during dose escalation. Serious adverse events are rare and similar between both drugs.
Can I switch from semaglutide to tirzepatide?
Switching is a decision for your prescribing provider. Tirzepatide is started at a low dose (2.5 mg) and increased gradually, at intervals of at least 4 weeks, to minimize GI side effects. Discuss the switch, your current dose and any side effects with your prescribing provider.
Who is tirzepatide better for vs semaglutide?
Tirzepatide may be preferable for patients who need greater weight loss (e.g., higher starting BMI, more comorbidities), have not achieved goals on semaglutide, or have type 2 diabetes requiring glucose control (Mounjaro has strong A1c-lowering data). Semaglutide may be preferred when cardiovascular risk reduction is a treatment goal (SELECT trial data), when someone has already responded well to GLP-1 therapy specifically, or based on prescriber and patient preference. This is a clinical decision, not a self-selection.
Clinical Research References
Sources & References
- Jastreboff AM, et al. "Tirzepatide Once Weekly for the Treatment of Obesity." NEJM. 2022;387(3):205–216. (SURMOUNT-1)
- Wilding JPH, et al. "Once-Weekly Semaglutide in Adults with Overweight or Obesity." NEJM. 2021;384:989–1002. (STEP-1)
- Aronne LJ, et al. "Tirzepatide as Compared with Semaglutide for the Treatment of Obesity." NEJM. 2025. DOI 10.1056/NEJMoa2416394. (Head-to-head RCT)
- Lincoff AM, et al. "Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes." NEJM. 2023;389:2221–2232. (SELECT trial)
- Frías JP, et al. "Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes." NEJM. 2021;385:503–515. (SURPASS-2)
- Drucker DJ. "GLP-1 physiology informs the pharmacotherapy of obesity." Molecular Metabolism. 2022;57:101351.